Literature DB >> 17882394

[Metabolic bone diseases].

F Jakob1.   

Abstract

Osteomalacia is caused by impaired vitamin D receptor (VDR) signaling, calcium deficiency, and altered bone mineralization. This can be due to insufficient sunlight exposure, malabsorption, reduced D hormone activation in chronic kidney disease, and rare alterations of VDR signaling and phosphate metabolism. Leading symptoms are bone pain, muscular cramps, and increased incidence of falls in the elderly. The adequate respective countermeasures are to optimize the daily intake of calcium and vitamin D3 and to replace active D hormone and phosphate if deficient. Osteoporosis is characterized by bone fragility fractures upon minor physical impact. Indications for diagnosis and treatment can be established by estimating the absolute fracture risk, taking into account bone mineral density, age, gender, and individual risk factors. Exercise, intervention programs to avoid falls, and specific drugs are capable of substantially reducing fracture risk even in the elderly. Secondary osteoporosis primarily requires both bone-altering medications and effective treatment of underlying diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882394     DOI: 10.1007/s00108-007-1934-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  180 in total

1.  Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia.

Authors:  Takao Kimizuka; Yutaka Ozaki; Yukiharu Sumi
Journal:  Ann Nucl Med       Date:  2004-02       Impact factor: 2.668

Review 2.  Bone densitometry and bone biopsy.

Authors:  Stuart H Ralston
Journal:  Best Pract Res Clin Rheumatol       Date:  2005-06       Impact factor: 4.098

3.  Quantitative Ultrasound--it is time to focus research efforts.

Authors:  Claus-C Glüer
Journal:  Bone       Date:  2006-09-01       Impact factor: 4.398

4.  Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).

Authors:  J D Ringe; P Farahmand; E Schacht; A Rozehnal
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

5.  The beneficial effects of group-based exercises on fall risk profile and physical activity persist 1 year postintervention in older women with low bone mass: follow-up after withdrawal of exercise.

Authors:  Teresa Y L Liu-Ambrose; Karim M Khan; Janice J Eng; Graham L Gillies; Stephen R Lord; Heather A McKay
Journal:  J Am Geriatr Soc       Date:  2005-10       Impact factor: 5.562

6.  Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice.

Authors:  John T Schousboe; C Rowan Debold
Journal:  Osteoporos Int       Date:  2005-09-20       Impact factor: 4.507

Review 7.  Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists.

Authors:  Paul D Miller
Journal:  Curr Rheumatol Rep       Date:  2005-03       Impact factor: 4.592

Review 8.  Genetic regulation of bone mass and susceptibility to osteoporosis.

Authors:  Stuart H Ralston; Benoit de Crombrugghe
Journal:  Genes Dev       Date:  2006-09-15       Impact factor: 11.361

Review 9.  Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

Authors:  Julie M Blair; Hong Zhou; Markus J Seibel; Colin R Dunstan
Journal:  Nat Clin Pract Oncol       Date:  2006-01

10.  Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials.

Authors:  Nguyen D Nguyen; John A Eisman; Tuan V Nguyen
Journal:  J Bone Miner Res       Date:  2006-02       Impact factor: 6.741

View more
  8 in total

1.  [New therapeutic approach in glucocorticoid-induce osteoporosis].

Authors:  F Jakob; S Nitschmann
Journal:  Internist (Berl)       Date:  2008-12       Impact factor: 0.743

Review 2.  [Diagnostics in osteology].

Authors:  F Jakob; F Genest; L Seefried; E Tsourdi; C Lapa; L C Hofbauer
Journal:  Internist (Berl)       Date:  2016-07       Impact factor: 0.743

3.  [Osteomalacia and vitamin D deficiency].

Authors:  C P Rader; N Corsten; O Rolf
Journal:  Orthopade       Date:  2015-09       Impact factor: 1.087

Review 4.  [Pathophysiology of bone metabolism].

Authors:  F Jakob; L Seefried; R Ebert
Journal:  Internist (Berl)       Date:  2008-10       Impact factor: 0.743

5.  [Clinical presentation and diagnosis of osteoporosis and osteomalacia].

Authors:  R Därr; V Ziller; P Hadji; L C Hofbauer
Journal:  Internist (Berl)       Date:  2008-10       Impact factor: 0.743

6.  [Reduced bone density and bone pain :osteomalacia with hypophospatemia and hypophosphaturia].

Authors:  H M Findeisen; C J Auernhammer; K G Parhofer; K A Herrmann; C la Fougere; C Weiler; R Bartl; E Koch
Journal:  Internist (Berl)       Date:  2009-12       Impact factor: 0.743

7.  Current Aspects of Fragility Fracture Repair.

Authors:  Stefan Grote; Wolfgang Boecker; Wolf Mutschler; Matthias Schieker
Journal:  Eur J Trauma Emerg Surg       Date:  2008-11-24       Impact factor: 3.693

Review 8.  [Endoprosthetic treatment of osteoporosis-related coxarthrosis : aspects of safe patient treatment].

Authors:  S Kirschner; A Hartmann; K-P Günther; C Hamann
Journal:  Orthopade       Date:  2014-04       Impact factor: 1.087

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.